{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:41:54Z","timestamp":1791870114461,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8057","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,4,3]]},"DOI":"10.1038\/s41586-025-08618-7","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:04:19Z","timestamp":1741190659000},"page":"265-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["A cryptic pocket in CB1 drives peripheral and functional selectivity"],"prefix":"10.1038","volume":"640","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9721-6195","authenticated-orcid":false,"given":"Vipin Ashok","family":"Rangari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2260-7722","authenticated-orcid":false,"given":"Evan S.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3191-7749","authenticated-orcid":false,"given":"Richard A.","family":"Slivicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachariah","family":"Bertels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9853-3347","authenticated-orcid":false,"given":"Kevin","family":"Appourchaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2758-2480","authenticated-orcid":false,"given":"Deniz","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-8956","authenticated-orcid":false,"given":"Nokomis","family":"Ramos-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5220-8239","authenticated-orcid":false,"given":"Juliet","family":"Mwirigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta","family":"Mangutov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana L.","family":"Sobecks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaseen","family":"Awad-Agbaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj B.","family":"Uphade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhoan","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teja Nikhil","family":"Peddada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shiimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-653X","authenticated-orcid":false,"given":"Xi-Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakayla","family":"Folarin-Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudh","family":"Kalathil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs R.","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-3990","authenticated-orcid":false,"given":"Brian K.","family":"Kobilka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9691-2976","authenticated-orcid":false,"given":"Amynah A.","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3154-4775","authenticated-orcid":false,"given":"Michael D.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2283-4033","authenticated-orcid":false,"given":"Kaavya Krishna","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2793","authenticated-orcid":false,"given":"Ron O.","family":"Dror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5428-4251","authenticated-orcid":false,"suffix":"IV","given":"Robert W.","family":"Gereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2931-3823","authenticated-orcid":false,"given":"Susruta","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"8618_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone, D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr. Opin. Psychiatry 34, 344\u2013350 (2021).","journal-title":"Curr. Opin. Psychiatry"},{"key":"8618_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1124\/jpet.117.246983","volume":"365","author":"TF Gamage","year":"2018","unstructured":"Gamage, T. F. et al. Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. J. Pharmacol. Exp. Ther. 365, 437\u2013446 (2018).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"8618_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1124\/pr.119.017863","volume":"71","author":"B Zarzycka","year":"2019","unstructured":"Zarzycka, B., Zaidi, S. A., Roth, B. L. & Katritch, V. Harnessing ion-binding sites for GPCR pharmacology. Pharmacol. Rev. 71, 571\u2013595 (2019).","journal-title":"Pharmacol. Rev."},{"key":"8618_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jpain.2015.05.002","volume":"16","author":"RL Nahin","year":"2015","unstructured":"Nahin, R. L. Estimates of pain prevalence and severity in adults: United States, 2012. J. Pain 16, 769\u2013780 (2015).","journal-title":"J. Pain"},{"key":"8618_CR5","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","volume":"397","author":"SP Cohen","year":"2021","unstructured":"Cohen, S. P., Vase, L. & Hooten, W. M. Chronic pain: an update on burden, best practices, and new advances. Lancet 397, 2082\u20132097 (2021).","journal-title":"Lancet"},{"key":"8618_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","volume":"26","author":"ND Volkow","year":"2021","unstructured":"Volkow, N. D. & Blanco, C. The changing opioid crisis: development, challenges and opportunities. Mol. Psychiatry 26, 218\u2013233 (2021).","journal-title":"Mol. Psychiatry"},{"key":"8618_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","volume":"74","author":"RG Pertwee","year":"1997","unstructured":"Pertwee, R. G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129\u2013180 (1997).","journal-title":"Pharmacol. Ther."},{"key":"8618_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neuropharm.2017.06.015","volume":"124","author":"SG Woodhams","year":"2017","unstructured":"Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G. & Neugebauer, V. The cannabinoid system and pain. Neuropharmacology 124, 105\u2013120 (2017).","journal-title":"Neuropharmacology"},{"key":"8618_CR9","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1021\/acschemneuro.9b00429","volume":"10","author":"DB Finlay","year":"2019","unstructured":"Finlay, D. B. et al. Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA. ACS Chem. Neurosci. 10, 4350\u20134360 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"8618_CR10","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1021\/acschemneuro.5b00112","volume":"6","author":"SD Banister","year":"2015","unstructured":"Banister, S. D. et al. Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem. Neurosci. 6, 1546\u20131559 (2015).","journal-title":"ACS Chem. Neurosci."},{"key":"8618_CR11","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/acschemneuro.6b00137","volume":"7","author":"SD Banister","year":"2016","unstructured":"Banister, S. D. et al. Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chem. Neurosci. 7, 1241\u20131254 (2016).","journal-title":"ACS Chem. Neurosci."},{"key":"8618_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.115.225326","volume":"354","author":"JL Wiley","year":"2015","unstructured":"Wiley, J. L. et al. AB-CHMINACA, AB-PINACA, and FUBIMINA: affinity and potency of novel synthetic cannabinoids in producing \u03949-tetrahydrocannabinol-like effects in mice. J. Pharmacol. Exp. Ther. 354, 328\u2013339 (2015).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"8618_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.phrs.2019.02.002","volume":"142","author":"RA Slivicki","year":"2019","unstructured":"Slivicki, R. A., Xu, Z., Mali, S. S. & Hohmann, A. G. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro. Pharmacol. Res. 142, 267\u2013282 (2019).","journal-title":"Pharmacol. Res."},{"key":"8618_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107847","volume":"164","author":"AN Henderson-Redmond","year":"2020","unstructured":"Henderson-Redmond, A. N. et al. c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner. Neuropharmacology 164, 107847 (2020).","journal-title":"Neuropharmacology"},{"key":"8618_CR15","doi-asserted-by":"publisher","first-page":"9.59.1","DOI":"10.1002\/cpns.31","volume":"80","author":"M Metna-Laurent","year":"2017","unstructured":"Metna-Laurent, M., Mond\u00e9sir, M., Grel, A., Vall\u00e9e, M. & Piazza, P.-V. Cannabinoid-induced tetrad in mice. Curr. Protoc. Neurosci. 80, 9.59.1\u20139.59.10 (2017).","journal-title":"Curr. Protoc. Neurosci."},{"key":"8618_CR16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/nn.2632","volume":"13","author":"JR Clapper","year":"2010","unstructured":"Clapper, J. R. et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat. Neurosci. 13, 1265\u20131270 (2010).","journal-title":"Nat. Neurosci."},{"key":"8618_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1124\/jpet.118.252288","volume":"367","author":"RA Slivicki","year":"2018","unstructured":"Slivicki, R. A. et al. Brain-permeant and -impermeant inhibitors of fatty acid amide hydrolase synergize with the opioid analgesic morphine to suppress chemotherapy-induced neuropathic nociception without enhancing effects of morphine on gastrointestinal transit. J. Pharmacol. Exp. Ther. 367, 551\u2013563 (2018).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"8618_CR18","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/j.pain.0000000000002550","volume":"163","author":"RA Slivicki","year":"2022","unstructured":"Slivicki, R. A., Yi, J., Brings, V. E., Huynh, P. N. & Gereau, R. W. The cannabinoid agonist CB-13 produces peripherally mediated analgesia in mice but elicits tolerance and signs of central nervous system activity with repeated dosing. Pain 163, 1603\u20131621 (2022).","journal-title":"Pain"},{"key":"8618_CR19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1124\/dmd.108.024000","volume":"37","author":"A Gardin","year":"2009","unstructured":"Gardin, A., Kucher, K., Kiese, B. & Appel-Dingemanse, S. Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety. Drug Metab. Dispos. 37, 827\u2013833 (2009).","journal-title":"Drug Metab. Dispos."},{"key":"8618_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bja.2021.10.020","volume":"128","author":"NC Ford","year":"2022","unstructured":"Ford, N. C. et al. Role of primary sensory neurone cannabinoid type-1 receptors in pain and the analgesic effects of the peripherally acting agonist CB-13 in mice. Br. J. Anaesth. 128, 159\u2013173 (2022).","journal-title":"Br. J. Anaesth."},{"key":"8618_CR21","doi-asserted-by":"publisher","first-page":"7525","DOI":"10.1021\/acs.jmedchem.6b00516","volume":"59","author":"HH Seltzman","year":"2016","unstructured":"Seltzman, H. H. et al. Peripherally selective cannabinoid 1 receptor (CB1R) agonists for the treatment of neuropathic pain. J. Med. Chem. 59, 7525\u20137543 (2016).","journal-title":"J. Med. Chem."},{"key":"8618_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.neuropharm.2018.07.002","volume":"139","author":"Y Mulpuri","year":"2018","unstructured":"Mulpuri, Y. et al. Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation. Neuropharmacology 139, 85\u201397 (2018).","journal-title":"Neuropharmacology"},{"key":"8618_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115665","volume":"214","author":"MK Piscura","year":"2023","unstructured":"Piscura, M. K. et al. Mechanisms of cannabinoid tolerance. Biochem. Pharmacol. 214, 115665 (2023).","journal-title":"Biochem. Pharmacol."},{"key":"8618_CR24","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.biopsych.2011.11.027","volume":"71","author":"PT Nguyen","year":"2012","unstructured":"Nguyen, P. T. et al. \u03b2-Arrestin2 regulates cannabinoid CB 1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biol. Psychiatry 71, 714\u2013724 (2012).","journal-title":"Biol. Psychiatry"},{"key":"8618_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.phrs.2017.08.008","volume":"125","author":"BM Ford","year":"2017","unstructured":"Ford, B. M. et al. Characterization of structurally novel G protein biased CB1 agonists: implications for drug development. Pharmacol. Res. 125, 161\u2013177 (2017).","journal-title":"Pharmacol. Res."},{"key":"8618_CR26","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1016\/j.cell.2023.11.017","volume":"186","author":"YY Liao","year":"2023","unstructured":"Liao, Y. Y. et al. Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism. Cell 186, 5784\u20135797.e17 (2023).","journal-title":"Cell"},{"key":"8618_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/978-3-642-41199-1_22","volume":"219","author":"KM Raehal","year":"2014","unstructured":"Raehal, K. M. & Bohn, L. M. \u03b2-Arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handb. Exp. Pharmacol. 219, 427\u2013443 (2014).","journal-title":"Handb. Exp. Pharmacol."},{"key":"8618_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/FBP.0b013e328308f1e6","volume":"19","author":"CS Breivogel","year":"2008","unstructured":"Breivogel, C. S., Lambert, J. M., Gerfin, S., Huffman, J. W. & Razdan, R. K. Sensitivity to \u03949-tetrahydrocannabinol is selectively enhanced in beta-arrestin2-\/- mice. Behav. Pharmacol. 19, 298\u2013307 (2008).","journal-title":"Behav. Pharmacol."},{"key":"8618_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1021\/acsptsci.9b00069","volume":"3","author":"E Wouters","year":"2020","unstructured":"Wouters, E. et al. Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds. ACS Pharmacol. Transl. Sci. 3, 285\u2013295 (2020).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"8618_CR30","doi-asserted-by":"publisher","first-page":"14257","DOI":"10.1021\/jacs.6b05425","volume":"138","author":"V Oleinikovas","year":"2016","unstructured":"Oleinikovas, V., Saladino, G., Cossins, B. P. & Gervasio, F. L. Understanding cryptic pocket formation in protein targets by enhanced sampling simulations. J. Am. Chem. Soc. 138, 14257\u201314263 (2016).","journal-title":"J. Am. Chem. Soc."},{"key":"8618_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2361","volume":"4","author":"CD Wassman","year":"2013","unstructured":"Wassman, C. D. et al. Computational identification of a transiently open L1\/S3 pocket for reactivation of mutant p53. Nat. Commun. 4, 1407 (2013).","journal-title":"Nat. Commun."},{"key":"8618_CR32","doi-asserted-by":"publisher","first-page":"106961","DOI":"10.1016\/j.phrs.2023.106961","volume":"197","author":"N Ramos-Gonzalez","year":"2023","unstructured":"Ramos-Gonzalez, N., Paul, B. & Majumdar, S. IUPHAR themed review: opioid efficacy, bias, and selectivity. Pharmacol. Res. 197, 106961 (2023).","journal-title":"Pharmacol. Res."},{"key":"8618_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/bph.15973","volume":"180","author":"JJ Manning","year":"2023","unstructured":"Manning, J. J., Rawcliffe, G., Finlay, D. B. & Glass, M. Cannabinoid 1 (CB1) receptor arrestin subtype-selectivity and phosphorylation dependence. Br. J. Pharmacol. 180, 369\u2013382 (2023).","journal-title":"Br. J. Pharmacol."},{"key":"8618_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41586-022-05588-y","volume":"613","author":"A Faouzi","year":"2023","unstructured":"Faouzi, A. et al. Structure-based design of bitopic ligands for the \u00b5-opioid receptor. Nature 613, 767\u2013774 (2023).","journal-title":"Nature"},{"key":"8618_CR35","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1021\/acscentsci.4c00525","volume":"10","author":"RS Ople","year":"2024","unstructured":"Ople, R. S. et al. Signaling modulation mediated by ligand water interactions with the sodium site at \u03bcOR. ACS Cent. Sci. 10, 1490\u20131503 (2024).","journal-title":"ACS Cent. Sci."},{"key":"8618_CR36","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.cell.2018.11.040","volume":"176","author":"K Krishna Kumar","year":"2019","unstructured":"Krishna Kumar, K. et al. Structure of a signaling cannabinoid receptor 1-G protein complex. Cell 176, 448\u2013458.e12 (2019).","journal-title":"Cell"},{"key":"8618_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37864-4","volume":"14","author":"K Krishna Kumar","year":"2023","unstructured":"Krishna Kumar, K. et al. Structural basis for activation of CB1 by an endocannabinoid analog. Nat. Commun. 14, 2672 (2023).","journal-title":"Nat. Commun."},{"key":"8618_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.56519","volume":"10","author":"R Uprety","year":"2021","unstructured":"Uprety, R. et al. Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site. eLife 10, 1\u201358 (2021).","journal-title":"eLife"},{"key":"8618_CR39","doi-asserted-by":"publisher","first-page":"13873","DOI":"10.1021\/acs.jmedchem.1c01273","volume":"64","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty, S. et al. A novel mitragynine analog with low-efficacy mu opioid receptor agonism displays antinociception with attenuated adverse effects. J. Med. Chem. 64, 13873\u201313892 (2021).","journal-title":"J. Med. Chem."},{"key":"8618_CR40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41589-022-01208-y","volume":"19","author":"Q Qu","year":"2023","unstructured":"Qu, Q. et al. Insights into distinct signaling profiles of the \u00b5OR activated by diverse agonists. Nat. Chem. Biol. 19, 423\u2013430 (2023).","journal-title":"Nat. Chem. Biol."},{"key":"8618_CR41","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1126\/science.aaz0326","volume":"367","author":"C-M Suomivuori","year":"2020","unstructured":"Suomivuori, C.-M. et al. Molecular mechanism of biased signaling in a prototypical G protein-coupled receptor. Science 367, 881\u2013887 (2020).","journal-title":"Science"},{"key":"8618_CR42","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.cell.2018.12.006","volume":"176","author":"LM Wingler","year":"2019","unstructured":"Wingler, L. M., McMahon, C., Staus, D. P., Lefkowitz, R. J. & Kruse, A. C. Distinctive activation mechanism for angiotensin receptor revealed by a synthetic nanobody. Cell 176, 479\u2013490.e12 (2019).","journal-title":"Cell"},{"key":"8618_CR43","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1021\/jm070317a","volume":"50","author":"EK Dziadulewicz","year":"2007","unstructured":"Dziadulewicz, E. K. et al. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1\/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J. Med. Chem. 50, 3851\u20133856 (2007).","journal-title":"J. Med. Chem."},{"key":"8618_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/3-540-26573-2_24","volume":"168","author":"AH Lichtman","year":"2005","unstructured":"Lichtman, A. H. & Martin, B. R. Cannabinoid tolerance and dependence. Handb. Exp. Pharmacol. 168, 691\u2013717 (2005).","journal-title":"Handb. Exp. Pharmacol."},{"key":"8618_CR45","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.pain.2013.10.004","volume":"155","author":"AA Pradhan","year":"2014","unstructured":"Pradhan, A. A. et al. Characterization of a novel model of chronic migraine. Pain 155, 269\u2013274 (2014).","journal-title":"Pain"},{"key":"8618_CR46","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1097\/j.pain.0000000000002214","volume":"162","author":"T Yamamoto","year":"2021","unstructured":"Yamamoto, T. et al. Selective targeting of peripheral cannabinoid receptors prevents behavioral symptoms and sensitization of trigeminal neurons in mouse models of migraine and medication overuse headache. Pain 162, 2246\u20132262 (2021).","journal-title":"Pain"},{"key":"8618_CR47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature11691","volume":"492","author":"J Besnard","year":"2012","unstructured":"Besnard, J. et al. Automated design of ligands to polypharmacological profiles. Nature 492, 215\u2013220 (2012).","journal-title":"Nature"},{"key":"8618_CR48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.euroneuro.2020.01.006","volume":"36","author":"JG Ramaekers","year":"2020","unstructured":"Ramaekers, J. G., Mason, N. L. & Theunissen, E. L. Blunted highs: pharmacodynamic and behavioral models of cannabis tolerance. Eur. Neuropsychopharmacol. 36, 191\u2013205 (2020).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"8618_CR49","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0376-8716(99)00150-7","volume":"60","author":"CE Bass","year":"2000","unstructured":"Bass, C. E. & Martin, B. R. Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend. 60, 113\u2013119 (2000).","journal-title":"Drug Alcohol Depend."},{"key":"8618_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.684115","volume":"8","author":"AN Henderson-Redmond","year":"2021","unstructured":"Henderson-Redmond, A. N. et al. Sex differences in tolerance to delta-9-tetrahydrocannabinol in mice with cisplatin-evoked chronic neuropathic pain. Front. Mol. Biosci. 8, 684115 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"8618_CR51","doi-asserted-by":"publisher","unstructured":"Slivicki, R. A. et al. Impact of \u03949-tetrahydrocannabinol and oxycodone co-administration on measures of antinociception, dependence, circadian activity, and reward in mice. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.12.04.569809 (2023).","DOI":"10.1101\/2023.12.04.569809"},{"key":"8618_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2018.07.014","volume":"93","author":"M Colizzi","year":"2018","unstructured":"Colizzi, M. & Bhattacharyya, S. Cannabis use and the development of tolerance: a systematic review of human evidence. Neurosci. Biobehav. Rev. 93, 1\u201325 (2018).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"8618_CR53","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1038\/sj.npp.1301643","volume":"33","author":"DC D\u2019Souza","year":"2008","unstructured":"D\u2019Souza, D. C. et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33, 2505\u20132516 (2008).","journal-title":"Neuropsychopharmacology"},{"key":"8618_CR54","doi-asserted-by":"publisher","first-page":"143S","DOI":"10.1002\/j.1552-4604.1981.tb02589.x","volume":"21","author":"RT Jones","year":"1981","unstructured":"Jones, R. T., Benowitz, N. L. & Herning, R. I. Clinical relevance of cannabis tolerance and dependence. J. Clin. Pharmacol. 21, 143S\u2013152S (1981).","journal-title":"J. Clin. Pharmacol."},{"key":"8618_CR55","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1089\/can.2016.0010","volume":"1","author":"C Cuttler","year":"2016","unstructured":"Cuttler, C., Mischley, L. K. & Sexton, M. Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users. Cannabis Cannabinoid Res. 1, 166\u2013175 (2016).","journal-title":"Cannabis Cannabinoid Res"},{"key":"8618_CR56","first-page":"9.59.1","volume":"2017","author":"M Metna-Laurent","year":"2017","unstructured":"Metna-Laurent, M., Mond\u00e9sir, M., Grel, A., Vall\u00e9e, M. & Piazza, P. V. Cannabinoid-induced tetrad in mice. Curr. Protoc. Neurosci. 2017, 9.59.1\u20139.59.10 (2017).","journal-title":"Curr. Protoc. Neurosci"},{"key":"8618_CR57","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1097\/j.pain.0000000000001278","volume":"159","author":"H Zhang","year":"2018","unstructured":"Zhang, H. et al. Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain. Pain 159, 1814\u20131823 (2018).","journal-title":"Pain"},{"key":"8618_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01538-1","volume":"24","author":"TP Do","year":"2023","unstructured":"Do, T. P., Hougaard, A., Dussor, G., Brennan, K. C. & Amin, F. M. Migraine attacks are of peripheral origin: the debate goes on. J. Headache Pain 24, 3 (2023).","journal-title":"J. Headache Pain"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08618-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:52:19Z","timestamp":1743814339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08618-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":58,"journal-issue":{"issue":"8057","published-print":{"date-parts":[[2025,4,3]]}},"alternative-id":["8618"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-08618-7","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M. is a founder of Sparian Biosciences. B.K.K. is a founder of and consultant for ConfometRx. R.O.D. holds equity in Septerna, Inc. S.M., V.A.R., R.W.G., Z.B., R.A.S., A.S.P., D.A. and R.O.D. have filed a patent\u00a0related to the lead compounds disclosed in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}